Literature DB >> 20449511

A panel of subunit-selective activity-based proteasome probes.

Martijn Verdoes1, Lianne I Willems, Wouter A van der Linden, Boudewijn A Duivenvoorden, Gijsbert A van der Marel, Bogdan I Florea, Alexei F Kisselev, Herman S Overkleeft.   

Abstract

Mammals express seven different catalytically active proteasome subunits. In order to determine the roles of the different proteolytically active subunits in antigen presentation and other cellular processes, highly specific inhibitors and activity-based probes that selectively target specific active sites are needed. In this work we present the development of fluorescent activity-based probes that selectively target the beta1 and beta5 sites of the constitutive proteasome.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20449511      PMCID： PMC3042124          DOI： 10.1039/c001036g

Source DB:  PubMed          Journal:  Org Biomol Chem        ISSN： 1477-0520            Impact factor:   3.876


  23 in total

1.  Approval summary for bortezomib for injection in the treatment of multiple myeloma.

Authors:  Peter F Bross; Robert Kane; Ann T Farrell; Sophia Abraham; Kimberly Benson; Margaret E Brower; Sean Bradley; Jogarao V Gobburu; Anwar Goheer; Shwu-Luan Lee; John Leighton; Cheng Yi Liang; Richard T Lostritto; William D McGuinn; David E Morse; Atiqur Rahman; Lilliam A Rosario; S Leigh Verbois; Grant Williams; Yong-Cheng Wang; Richard Pazdur
Journal:  Clin Cancer Res       Date:  2004-06-15       Impact factor: 12.531

2.  Identification of the yeast 20S proteasome catalytic centers and subunit interactions required for active-site formation.

Authors:  C S Arendt; M Hochstrasser
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-08       Impact factor: 11.205

3.  Selective inhibitor of proteasome's caspase-like sites sensitizes cells to specific inhibition of chymotrypsin-like sites.

Authors:  Matthew Britton; Marcella M Lucas; Sondra L Downey; Michael Screen; Alexandre A Pletnev; Martijn Verdoes; Robert A Tokhunts; Omar Amir; Ayrton L Goddard; Philip M Pelphrey; Dennis L Wright; Herman S Overkleeft; Alexei F Kisselev
Journal:  Chem Biol       Date:  2009-12-24

4.  The active sites of the eukaryotic 20 S proteasome and their involvement in subunit precursor processing.

Authors:  W Heinemeyer; M Fischer; T Krimmer; U Stachon; D H Wolf
Journal:  J Biol Chem       Date:  1997-10-03       Impact factor: 5.157

5.  Covalent modification of the active site threonine of proteasomal beta subunits and the Escherichia coli homolog HslV by a new class of inhibitors.

Authors:  M Bogyo; J S McMaster; M Gaczynska; D Tortorella; A L Goldberg; H Ploegh
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-24       Impact factor: 11.205

6.  Autocatalytic subunit processing couples active site formation in the 20S proteasome to completion of assembly.

Authors:  P Chen; M Hochstrasser
Journal:  Cell       Date:  1996-09-20       Impact factor: 41.582

Review 7.  Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy.

Authors:  Robert C Kane; Peter F Bross; Ann T Farrell; Richard Pazdur
Journal:  Oncologist       Date:  2003

8.  Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids.

Authors:  J Adams; M Behnke; S Chen; A A Cruickshank; L R Dick; L Grenier; J M Klunder; Y T Ma; L Plamondon; R L Stein
Journal:  Bioorg Med Chem Lett       Date:  1998-02-17       Impact factor: 2.823

9.  Substrate binding and sequence preference of the proteasome revealed by active-site-directed affinity probes.

Authors:  M Bogyo; S Shin; J S McMaster; H L Ploegh
Journal:  Chem Biol       Date:  1998-06

10.  Immunoproteasome assembly: cooperative incorporation of interferon gamma (IFN-gamma)-inducible subunits.

Authors:  T A Griffin; D Nandi; M Cruz; H J Fehling; L V Kaer; J J Monaco; R A Colbert
Journal:  J Exp Med       Date:  1998-01-05       Impact factor: 14.307
View more
  15 in total

1.  Nature of pharmacophore influences active site specificity of proteasome inhibitors.

Authors:  Michael Screen; Matthew Britton; Sondra L Downey; Martijn Verdoes; Mathias J Voges; Annet E M Blom; Paul P Geurink; Martijn D P Risseeuw; Bogdan I Florea; Wouter A van der Linden; Alexandre A Pletnev; Herman S Overkleeft; Alexei F Kisselev
Journal:  J Biol Chem       Date:  2010-10-11       Impact factor: 5.157

Review 2.  Proteasome inhibitors: an expanding army attacking a unique target.

Authors:  Alexei F Kisselev; Wouter A van der Linden; Herman S Overkleeft
Journal:  Chem Biol       Date:  2012-01-27

3.  Relative quantification of proteasome activity by activity-based protein profiling and LC-MS/MS.

Authors:  Nan Li; Chi-Lin Kuo; Guillem Paniagua; Hans van den Elst; Martijn Verdoes; Lianne I Willems; Wouter A van der Linden; Mark Ruben; Eric van Genderen; Jacob Gubbens; Gilles P van Wezel; Herman S Overkleeft; Bogdan I Florea
Journal:  Nat Protoc       Date:  2013-05-23       Impact factor: 13.491

4.  An inhibitor of proteasome β2 sites sensitizes myeloma cells to immunoproteasome inhibitors.

Authors:  Sondra Downey-Kopyscinski; Ellen W Daily; Marc Gautier; Ananta Bhatt; Bogdan I Florea; Constantine S Mitsiades; Paul G Richardson; Christoph Driessen; Herman S Overkleeft; Alexei F Kisselev
Journal:  Blood Adv       Date:  2018-10-09

5.  Inhibition of the Proteasome β2 Site Sensitizes Triple-Negative Breast Cancer Cells to β5 Inhibitors and Suppresses Nrf1 Activation.

Authors:  Emily S Weyburne; Owen M Wilkins; Zhe Sha; David A Williams; Alexandre A Pletnev; Gerjan de Bruin; Hermann S Overkleeft; Alfred L Goldberg; Michael D Cole; Alexei F Kisselev
Journal:  Cell Chem Biol       Date:  2017-01-26       Impact factor: 8.116

6.  Discovery of a potent and highly β1 specific proteasome inhibitor from a focused library of urea-containing peptide vinyl sulfones and peptide epoxyketones.

Authors:  Wouter A van der Linden; Lianne I Willems; Tamer B Shabaneh; Nan Li; Mark Ruben; Bogdan I Florea; Gijs A van der Marel; Markus Kaiser; Alexei F Kisselev; Herman S Overkleeft
Journal:  Org Biomol Chem       Date:  2011-11-22       Impact factor: 3.876

7.  Proteaphagy in Mammalian Cells Can Function Independent of ATG5/ATG7.

Authors:  Tatjana Goebel; Simone Mausbach; Andreas Tuermer; Heba Eltahir; Dominic Winter; Volkmar Gieselmann; Melanie Thelen
Journal:  Mol Cell Proteomics       Date:  2020-04-16       Impact factor: 5.911

8.  Incorporation of non-natural amino acids improves cell permeability and potency of specific inhibitors of proteasome trypsin-like sites.

Authors:  Paul P Geurink; Wouter A van der Linden; Anne C Mirabella; Nerea Gallastegui; Gerjan de Bruin; Annet E M Blom; Mathias J Voges; Elliot D Mock; Bogdan I Florea; Gijs A van der Marel; Christoph Driessen; Mario van der Stelt; Michael Groll; Herman S Overkleeft; Alexei F Kisselev
Journal:  J Med Chem       Date:  2013-01-28       Impact factor: 7.446

Review 9.  Activity-based imaging probes of the proteasome.

Authors:  Kimberly Cornish Carmony; Kyung Bo Kim
Journal:  Cell Biochem Biophys       Date:  2013-09       Impact factor: 2.194

Review 10.  Methods for the discovery of small molecules to monitor and perturb the activity of the human proteasome.

Authors:  Marianne E Maresh; Andres F Salazar-Chaparro; Darci J Trader
Journal:  Future Med Chem       Date:  2020-12-04       Impact factor: 3.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.